MedTrace Logo

Rituximab and RASi in Patients with IgAN

NCT04525729 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2025-03-14

No results posted yet for this study

Summary

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

Conditions

Interventions

DRUG

Rituximab

To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.

DRUG

RAS 2410

To evaluate the efficacy and safety of RASi in patients with IgAN.

Sponsors & Collaborators

  • Dongfang Hospital Affiliated to Tongji University

    collaborator OTHER

  • Shanghai Pudong New Area People's Hospital

    collaborator OTHER

  • Ruijin Hospital North Shanghai Jiao Tong University School of Medicine

    collaborator UNKNOWN

  • Ningbo Municipal Yinzhou District No.2 Hospital

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Xiamen Hong'ai Hospital

    collaborator UNKNOWN

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Tongji Hospital

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Nan Chen,MD

    lead OTHER

Principal Investigators

  • Jingyuan Xie · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2024-03-30
Completion
2024-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04525729 on ClinicalTrials.gov